BioGeneration Ventures

What BioGeneration Ventures does

BioGeneration Ventures (BGV) is a Netherlands-based venture capital firm founded in 2006 and headquartered in Naarden, specializing in seed and early-stage investment in European life sciences companies. The firm operates multiple fund vehicles — BGV III, BGV IV, BGV V, and the FIRST (Fonds InvesteringsRijpe Starters) fund — aggregating to over €100 million under management, and typically acts as lead investor. BGV targets innovative early-stage biotech, medtech, and diagnostics companies developing disruptive solutions for high unmet medical needs, applying a hands-on model in which partners take supervisory and interim management roles in portfolio companies.

The firm generates economic value through a combination of management fees on committed capital, capital appreciation on equity stakes, and carried interest from exits. BGV's track record includes co-founding Acerta Pharma, which developed Calquence (acalabrutinib) and was sold to AstraZeneca for up to USD 7 billion in 2016 (the largest private European biotech exit), and co-founding Dezima Pharma, sold to Amgen for up to USD 1.55 billion in 2015. More recently, BGV led a €21.5 million Series A extension in TargED Biopharmaceuticals (December 2025) and participated in Azafaros' €132 million Series B (May 2025), with portfolio exit TigaTx acquired by Epsiologen in April 2025.

BGV's go-to-market is direct investment with operational engagement: a team of approximately 44 life-science experts and business analysts sourced from large pharma (J&J, Merck KGaA, GSK, Roche, Ipsen) and biotech founder-operators provides company creation, supervisory board participation, and interim executive leadership. The firm is led by founder and Managing Partner Edward van Wezel alongside Managing Partner Oskar Slotboom, General Partner Daniela Couto, and Partner Keno Gutierrez, with a broader venture partner bench. BGV closely collaborates with Forbion, maintains an active presence across the Netherlands, UK, and Germany, and has institutional representation through Daniela Couto's Invest Europe Board seat and Silva Dezelan's ESG committee roles.

Name

BioGeneration Ventures

Legal name

BioGeneration Ventures

Website

http://www.biogenerationventures.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1–10 employees

Short description

BioGeneration Ventures is a Netherlands-based venture capital firm founded in 2006 that invests as lead investor in seed and early-stage European life sciences companies developing therapies for high unmet medical needs, managing over €100 million across multiple fund vehicles.

Ownership category

akta.pro rank

Product category

Venture Capital / Life Sciences Investment

NAICS

Funds, Trusts, and Other Financial Vehicles (525), Open-End Investment Funds (525910), Other Financial Vehicles (52599)

akta.pro primary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

Keywords

• Venture capital investing
• Early-stage biotech funding
• Life sciences investment
• Seed-stage biotech financing
• European healthcare venture capital

Headquarters

HQ city

Naarden

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Investment Returns and Management Fees: BGV generates revenue through returns on investments in portfolio companies, management fees from funds under management, and carried interest from successful exits. The firm has achieved significant returns through successful divestments including Acerta Pharma (sold to AstraZeneca for up to USD 7 billion) and Dezima Pharma (sold to Amgen for up to USD 1.55 billion).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

BioGeneration Ventures (BGV) is a venture capital firm that provides seed-stage investment to innovative early-stage European life sciences companies (biotech, medtech, and diagnostics). The firm generally acts as lead investor, taking a hands-on approach to provide sector-relevant operational and management expertise that accelerates product development and shapes companies into attractive investment opportunities for follow-on investors and acquirers.

Product overview

BioGeneration Ventures (BGV) is a venture capital firm that specializes in seed investment for innovative early-stage European life sciences companies. Rather than a unified product platform, BGV operates multiple investment funds (BGV III, BGV IV, BGV V, FIRST) that provide funding and operational expertise to portfolio companies developing disruptive biotech solutions for unmet medical needs. The firm leverages extensive industry experience and networks to shape companies into attractive investment opportunities.

Differentiator

Problem solved

Functional benefit

Brands

• FIRST (Fonds InvesteringsRijpe Starters): An investment fund managed by BGV focused on early-stage life sciences ventures.
• BGV III
• BGV IV
• BGV V

Products and services

• BioGeneration Ventures Fund Management Services

Quantifiable outcome

• Largest exit ever of a privately held European biotech company - Acerta Pharma sold to AstraZeneca for up to USD 7 billion
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• ForbioncoreStrategic or Co-development PartnerBGV closely collaborates with Forbion, a joint venture partner. The two firms share expertise, networks, and resources in the European life sciences venture capital space. Forbion Capital Partners is BGV's joint venture partner, with Managing Partner Sander Slootweg from Forbion appointed as Chairperson of Invest Europe for the 2026-2027 term.
• Invest EuropecoreStrategic or Co-development PartnerDaniela Couto, General Partner at BGV, was elected to the Invest Europe Board as a representative of the Venture Capital Platform. This appointment reflects BGV's commitment to supporting entrepreneurial scientists and building innovative life sciences companies across Europe. Invest Europe is a leading organization shaping dialogue around venture capital, innovation, and investment policy in Europe.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Forbion: Forbion is a leading European life sciences venture capital firm based in the Netherlands that BGV closely collaborates with as a joint venture partner. Both firms invest in early-to-growth-stage European biotech, share networks and resources, and co-invest in portfolio companies such as Azafaros.
• INKEF Capital: INKEF Capital is a Dutch-based venture capital firm focused on early-stage technology and healthcare/life sciences investments. It is directly comparable as a European early-stage life sciences investor with a similar AUM range and stage focus.
• LSP (Life Sciences Partners): LSP is one of Europe's largest and most established life sciences venture capital firms, investing across early and growth-stage biotech and medtech. It is comparable to BGV as a pan-European, sector-specialist life sciences VC with a long track record of exits.
• Seroba Life Sciences: Seroba is a European life sciences venture capital firm focused on early-stage biotech and medtech, and is a co-investor alongside BGV in portfolio companies such as Azafaros. Highly comparable in stage, sector, and European geography.
• Kurma Partners: Kurma Partners, part of Eurazeo, is a European healthcare and life sciences venture capital firm investing in early-stage biotech, medtech, and digital health. Kurma is a co-investor in BGV portfolio companies (e.g., TargED), making it a directly comparable peer.
• M Ventures: M Ventures is the corporate venture capital arm of Merck KGaA, investing in early-stage biotech and technology. Several BGV team members (including Keno Gutierrez and Joern-Peter Halle) previously served at M Ventures, making it a closely comparable sector-specialist investor.
• Jeito Capital: Jeito Capital is a European life sciences-dedicated venture capital firm that led the €132M Series B in Azafaros alongside BGV. It is directly comparable as an early-to-growth European biotech investor.
• Omega Funds: Omega Funds is a healthcare-dedicated investment manager that invests across biotech stages in Europe and the US. Keno Gutierrez previously held investment roles at Omega Funds, and the firm is a comparable sector-specialist life sciences investor.
• Novo Seeds (Novo Holdings): Novo Seeds is the early-stage venture arm of Novo Holdings, investing in Danish and broader European biotech and medtech at the seed and Series A stage. It is comparable as a sector-specialist, early-stage European life sciences VC.
• Atlas Venture: Atlas Venture is a leading early-stage life sciences venture capital firm that creates and funds biotech startups, primarily in the US but with cross-border deal flow. It is comparable in stage focus (seed/Series A biotech) and company-creation model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biogeneration-ventures

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments63 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioGeneration Ventures